KAZIA THERAPEUTICS LTD (KZIA) Form 424B3 — Aug 31, 2026
Kazia Therapeutics filed a 424B3 prospectus supplement on August 31, 2026 to update and supplement its prospectus dated December 22, 2025, which forms part of its Form F-1 registration statement (No. 333-276774) covering 95,110 American Depositary Shares representing 47,555,000 ordinary shares. The only new substantive information comes from an attached Form 6-K disclosing that the company launched a new website, www.kaziatx.com, replacing references to www.kaziatherapeutics.com, designed to give investors and stakeholders enhanced access to business, clinical-trial, and corporate information.
Key figures
- Ads Covered
- 95,110
- Implied Ads Ratio
- 1 ADS per 500 ordinary shares (derived from stated counts)
- Ordinary Shares Represented
- 47,555,000
- Last Reported Sale Price Per Ads
- $13.58 (August 28, 2026)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.